These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29733658)

  • 21. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor.
    Kobayashi H; Sakahara H; Hosono M; Yao ZS; Toyama S; Endo K; Konishi J
    J Nucl Med; 1994 Oct; 35(10):1677-84. PubMed ID: 7931671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.
    Heryanto YD; Hanaoka H; Nakajima T; Yamaguchi A; Tsushima Y
    Ann Nucl Med; 2017 Nov; 31(9):669-677. PubMed ID: 28741052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Characterization of the Radioimmunoconjugate
    Funase Y; Nakamura E; Kajita M; Saito Y; Oshikiri S; Kitano M; Tokura M; Hino A; Uehara T
    J Nucl Med; 2021 Feb; 62(2):232-239. PubMed ID: 32737245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
    Nayak TK; Garmestani K; Baidoo KE; Milenic DE; Brechbiel MW
    Int J Cancer; 2011 Feb; 128(4):920-6. PubMed ID: 20473899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous avidin chase improved localization of radiolabeled streptavidin in intraperitoneal xenograft pretargeted with biotinylated antibody.
    Zhang M; Sakahara H; Yao Z; Saga T; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
    Nucl Med Biol; 1997 Jan; 24(1):61-4. PubMed ID: 9080476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic efficacy of c-kit-targeted radioimmunotherapy using 90Y-labeled anti-c-kit antibodies in a mouse model of small cell lung cancer.
    Yoshida C; Tsuji AB; Sudo H; Sugyo A; Kikuchi T; Koizumi M; Arano Y; Saga T
    PLoS One; 2013; 8(3):e59248. PubMed ID: 23516616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
    Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.
    Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T
    Oncotarget; 2016 Jun; 7(25):38835-38844. PubMed ID: 27246980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
    Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
    Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and toxicity of radioimmunotherapy with (90)Y-DOTA-peptide-ChL6 for PC3-tumored mice.
    O'Donnell RT; DeNardo SJ; DeNardo GL; Miers L; Lamborn KR; Kukis DL; Meyers FJ
    Prostate; 2000 Aug; 44(3):187-92. PubMed ID: 10906734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Local Injection of Bevacizumab against Triple-Negative Breast Cancer Xenograft Tumors.
    Jiang X; Zhang QL; Liu TG; Zhao WP; Yang M; Wang LN; Sun WL; Pan L; Luo AP; Huang JC; Gu XH
    Curr Pharm Des; 2019; 25(8):862-870. PubMed ID: 30848190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?
    Grana C; Bartolomei M; Handkiewicz D; Rocca P; Bodei L; Colombo N; Chinol M; Mangioni C; Malavasi F; Paganelli G
    Gynecol Oncol; 2004 Jun; 93(3):691-8. PubMed ID: 15196866
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Ehlerding EB; Ferreira CA; Aluicio-Sarduy E; Jiang D; Lee HJ; Theuer CP; Engle JW; Cai W
    Mol Pharm; 2018 Jul; 15(7):2606-2613. PubMed ID: 29787283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined treatment of pancreatic cancer xenograft with
    Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T; Higashi T
    World J Gastroenterol; 2017 Nov; 23(42):7551-7562. PubMed ID: 29204055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: preinjection of intact antibody versus clearance of antigen with adivin-biotin system.
    Kobayashi H; Sun BF; Yoo TM; Le N; Kim MK; Paik CH; Pastan I; Waldmann TA; Carrasquillo JA
    J Nucl Med; 1999 Aug; 40(8):1381-91. PubMed ID: 10450692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.